First-dose pharmacokinetics of lithium carbonate in children and adolescents.
This study examines the pharmacokinetics of oral doses of lithium carbonate immediate-release capsules after administration of 600 or 900 mg in children and adolescents with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, bipolar I disorder. Lithium plasma concentrations were followed over 48 to 72 hours in 39 subjects (20 male and 19 female subjects; ages, 7-17 years) with mixed or manic episodes enrolled at 7 clinical sites participating in the Collaborative Lithium Trials. Population pharmacokinetic modeling was performed using NONMEM, and influences of patient covariates on pharmacokinetics parameters were examined. The pharmacokinetics of lithium was best described using a 2-compartment model with a lag time and first-order absorption. There was considerable variability in lithium exposures. Lithium clearance related best to fat-free mass. Inclusion of fat-free mass as a covariate reduced the between-subject variability from 52% to 42%. Lithium clearances did not vary systematically with age group, dose, sex, or creatinine clearances. Allometrically scaled clearance and volume of distribution from the population analysis were within the range reported in adults. Single-dose profiles of lithium in young patients with BP-1 show marked variability. Therefore, ongoing serum monitoring is needed during continued therapy. The developed population pharmacokinetic model may be used to predict other dosage regimens, support scaling from adult to pediatric pharmacokinetics, and support the design of future clinical trials.
Findling
Robert L
RL
University Hospitals, Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Landersdorfer
Cornelia B
CB
Kafantaris
Vivian
V
Pavuluri
Mani
M
McNamara
Nora K
NK
McClellan
Jon
J
Frazier
Jean A
JA
Sikich
Linmarie
L
Kowatch
Robert
R
Lingler
Jacqui
J
Faber
Jon
J
Taylor-Zapata
Perdita
P
Jusko
William J
WJ
D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D018692:Antimanic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002648:Child; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D008954:Models, Biological; D017711:Nonlinear Dynamics; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D014018:Tissue Distribution
D018692:Antimanic Agents; D016651:Lithium Carbonate